View as cardsView as table106 Projects

CNS drug delivery by identifying small molecule inhibitors of a newly identified key regulator of the blood brain barrier

Fiscal Year Awarded:

2022

Principal Investigator:

Chenghua Gu

Development of a novel monoclonal antibody that targets SARS-CoV-2 3a

Fiscal Year Awarded:

2022

Principal Investigator:

John Mekalanos

Enzyme prospecting for better diagnostics

Fiscal Year Awarded:

2022

Principal Investigator:

Michael Springer

Gene therapy for the treatment of Wolfram Syndrome II

Fiscal Year Awarded:

2022

Principal Investigator:

Amy Wagers

Novel biologics for cancer therapy

Fiscal Year Awarded:

2022

Principal Investigator:

George Church

Small molecule drugs for advanced cancer with ecDNA amplicons

Fiscal Year Awarded:

2022

Principal Investigator:

Timothy Mitchison

Small molecule modulators of bile acid metabolism to treat NAFLD/NASH

Fiscal Year Awarded:

2022

Principal Investigator:

Sloan Devlin

Studies on immunogenic lipids from the gut microbiome

Fiscal Year Awarded:

2022

Principal Investigator:

Jon Clardy

A novel biologic and therapeutic target for the treatment of diabetes

Fiscal Year Awarded:

2021

Principal Investigator:

Douglas Melton

Application of the SPLANDID antigen presentation technology to HIV-1 vaccine development

Fiscal Year Awarded:

2021

Principal Investigator:

James Chou

Development of an inexpensive at-home influenza kit and detection technology

Fiscal Year Awarded:

2021

Principal Investigator:

Michael Springer

Evaluating splicing modulators for therapeutic impact in cohesin-mutant AML and MDS cells

Fiscal Year Awarded:

2021

Principal Investigator:

Karen Adelman

Identifying novel therapeutic targets for treating pain and chronic itch

Fiscal Year Awarded:

2021

Principal Investigator:

David Ginty

Protein therapeutics for treatment of chronic and inflammatory pain

Fiscal Year Awarded:

2021

Principal Investigator:

Pamela Silver

Structure-guided discovery of novel antibiotics inhibiting bacterial cell wall formation

Fiscal Year Awarded:

2021

Principal Investigator:

Maofu Liao

Target identification of neuroprotective kinase inhibitors for Alzheimer’s and related dementias

Fiscal Year Awarded:

2021

Principal Investigator:

Mark Albers

A high-throughput platform for the non-invasive intracellular delivery of molecules for therapeutic applications

Fiscal Year Awarded:

2020

Principal Investigator:

Johan Paulsson

Developing novel therapeutic approaches for CNS drug delivery by targeting a newly identified key regulator of the blood brain barrier

Fiscal Year Awarded:

2020

Principal Investigator:

Chenghua Gu

Development of synthetic analogs of a sleeve gastrectomy-induced metabolite as a novel therapy for type 2 diabetes and obesity

Fiscal Year Awarded:

2020

Principal Investigator:

Sloan Devlin

Engineered proteins for treatment of pancreatitis

Fiscal Year Awarded:

2020

Principal Investigator:

Pamela Silver